ViroPharma

Skip to results list

Active filters:

33 items
Column grid
Column grid

Filter

Active filters:

About ViroPharma

Ghost Corp Apparel — resurrecting iconic corporate ghosts.

Founded in 1994, ViroPharma Incorporated grew from Exton, Pennsylvania into a specialty pharmaceutical company aimed at difficult diseases and specialist care. Its work ranged from anti-infective medicines to treatments for rare conditions—serious business, delivered from a very suburban corporate address.

ViroPharma’s early commercial identity was closely tied to Vancocin, an oral antibiotic treatment. In October 2008, it acquired Lev Pharmaceuticals, bringing Cinryze into the fold. Cinryze, used for routine prevention of hereditary angioedema attacks, helped shift the company further toward rare-disease medicine. The company also developed and licensed candidates including maribavir, because apparently one pipeline was never enough paperwork.

Shire announced its planned purchase of ViroPharma in November 2013. The transaction closed on January 24, 2014, when Shire acquired ViroPharma for $50 per share in cash, or approximately $4.2 billion. ViroPharma shares then stopped trading on NASDAQ, ending the independent public-company chapter of the Exton operation.

Our ViroPharma collection celebrates the lab-coat-and-conference-call era: an Exton biotech story that moved from antiviral ambitions and Vancocin capsules to rare-disease scale, then vanished into a larger pharmaceutical constellation.